Dec. 30 at 11:21 PM
$OTLC On December 23, 2025, Oncotelic Therapeutics, Inc. completed subscription agreements with 21 accredited investors for 32 units in a private offering of up to 500 units, each consisting of a
$25,000, 12% two-year note convertible into either Oncotelic or EdgePoint AI stock, along with associated warrants in both companies subject to anti-dilution protections. The transaction, which also refinances the company’s 2023 PPM note and extends prior warrant expirations by two years while allowing investors to swap EdgePoint shares into Oncotelic stock, enhances capital flexibility and investor optionality and is supported by a registration rights agreement for underlying Oncotelic shares, potentially strengthening the company’s financing position without relying on public registration at this stage.
